ALKS
$19.69
Alkermes Plc
($.35)
(1.75%)
ALKS
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.15)
Revenue:  $235.37 Mil
Thursday
Jul 23
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALKS reports earnings?
Beat
Meet
Miss

Where is ALKS's stock price going from here?
Up
Flat
Down
Stock chart of ALKS
Analysts
Summary of analysts' recommendations for ALKS
Score
Grade
Pivots
Resistance
$20.92
$20.58
$20.14

$19.80

Support
$19.36
$19.02
$18.58
Tweet
Growth
Description
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.
Peers
Regeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalInterCeptJohnson & JohnsonZoetisUltragenyx PharmaceuticalMylanCatalentBristol-Myers Squibb